AR057576A1 - Derivados sustituidos de pirrolidin-quinazolinas inhibidores de canales de sodio dependientes de voltaje, composiciones farmaceuticas que los contienen y usos, entre otros, en el tratamiento de una variedad de condiciones de dolor - Google Patents
Derivados sustituidos de pirrolidin-quinazolinas inhibidores de canales de sodio dependientes de voltaje, composiciones farmaceuticas que los contienen y usos, entre otros, en el tratamiento de una variedad de condiciones de dolorInfo
- Publication number
- AR057576A1 AR057576A1 ARP060104980A ARP060104980A AR057576A1 AR 057576 A1 AR057576 A1 AR 057576A1 AR P060104980 A ARP060104980 A AR P060104980A AR P060104980 A ARP060104980 A AR P060104980A AR 057576 A1 AR057576 A1 AR 057576A1
- Authority
- AR
- Argentina
- Prior art keywords
- aliphatic
- quinazolinyl
- pyrrolidinyl
- hydroxyphenyl
- methyl
- Prior art date
Links
- 229910052708 sodium Inorganic materials 0.000 title abstract 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000011734 sodium Substances 0.000 title 1
- 125000001931 aliphatic group Chemical group 0.000 abstract 13
- 229910052717 sulfur Inorganic materials 0.000 abstract 12
- 229920006395 saturated elastomer Polymers 0.000 abstract 11
- -1 CH2 radicals Chemical class 0.000 abstract 9
- 229910052760 oxygen Inorganic materials 0.000 abstract 9
- 229910052739 hydrogen Inorganic materials 0.000 abstract 8
- 239000001257 hydrogen Substances 0.000 abstract 8
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- 229910052757 nitrogen Inorganic materials 0.000 abstract 7
- 125000003342 alkenyl group Chemical group 0.000 abstract 6
- 125000005842 heteroatom Chemical group 0.000 abstract 6
- 125000001424 substituent group Chemical group 0.000 abstract 6
- 239000002253 acid Substances 0.000 abstract 4
- 150000002148 esters Chemical class 0.000 abstract 4
- 125000005843 halogen group Chemical group 0.000 abstract 4
- IVCWPRZMIBQEIF-BTQNPOSSSA-N FC(C(=O)O)(F)F.OC1=C(C=CC=C1)C1=NC2=CC(=CC=C2C(=N1)N1C[C@@H](CC1)NC(O)=O)C Chemical compound FC(C(=O)O)(F)F.OC1=C(C=CC=C1)C1=NC2=CC(=CC=C2C(=N1)N1C[C@@H](CC1)NC(O)=O)C IVCWPRZMIBQEIF-BTQNPOSSSA-N 0.000 abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 3
- 150000002431 hydrogen Chemical class 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 3
- 239000001301 oxygen Chemical group 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 239000011593 sulfur Chemical group 0.000 abstract 3
- 125000004429 atom Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 abstract 1
- WZTRDTYWUDRLFE-CYBMUJFWSA-N [(3R)-1-[2-(2-hydroxyphenyl)-7-methylquinazolin-4-yl]pyrrolidin-3-yl]carbamic acid Chemical compound CC1=CC=C2C(=C1)N=C(N=C2N1CC[C@H](C1)NC(O)=O)C1=C(O)C=CC=C1 WZTRDTYWUDRLFE-CYBMUJFWSA-N 0.000 abstract 1
- WZTRDTYWUDRLFE-ZDUSSCGKSA-N [(3S)-1-[2-(2-hydroxyphenyl)-7-methylquinazolin-4-yl]pyrrolidin-3-yl]carbamic acid Chemical compound CC1=CC=C2C(=C1)N=C(N=C2N1CC[C@@H](C1)NC(O)=O)C1=C(O)C=CC=C1 WZTRDTYWUDRLFE-ZDUSSCGKSA-N 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 150000004702 methyl esters Chemical class 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 229910052698 phosphorus Inorganic materials 0.000 abstract 1
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73733005P | 2005-11-14 | 2005-11-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR057576A1 true AR057576A1 (es) | 2007-12-05 |
Family
ID=38049182
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060104980A AR057576A1 (es) | 2005-11-14 | 2006-11-14 | Derivados sustituidos de pirrolidin-quinazolinas inhibidores de canales de sodio dependientes de voltaje, composiciones farmaceuticas que los contienen y usos, entre otros, en el tratamiento de una variedad de condiciones de dolor |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US8158637B2 (https=) |
| EP (1) | EP1957482B1 (https=) |
| JP (1) | JP2009515892A (https=) |
| KR (1) | KR20080073749A (https=) |
| CN (1) | CN101356168A (https=) |
| AR (1) | AR057576A1 (https=) |
| AT (1) | ATE540033T1 (https=) |
| AU (1) | AU2006315675B2 (https=) |
| CA (1) | CA2628650A1 (https=) |
| ES (1) | ES2377988T3 (https=) |
| MX (1) | MX2008006303A (https=) |
| NO (1) | NO20082746L (https=) |
| NZ (1) | NZ568393A (https=) |
| RU (1) | RU2008123811A (https=) |
| TW (1) | TW200804348A (https=) |
| WO (1) | WO2007058989A2 (https=) |
| ZA (1) | ZA200804043B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7713983B2 (en) * | 2003-03-03 | 2010-05-11 | Vertex Pharmaceuticals Incorporated | Quinazolines useful as modulators of ion channels |
| CL2004000409A1 (es) | 2003-03-03 | 2005-01-07 | Vertex Pharma | Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu |
| US7928107B2 (en) | 2004-09-02 | 2011-04-19 | Vertex Pharmaceuticals Incorporated | Quinazolines useful as modulators of ion channels |
| US7718658B2 (en) * | 2004-09-02 | 2010-05-18 | Vertex Pharmaceuticals Incorporated | Quinazolines useful as modulators of ion channels |
| US8283354B2 (en) * | 2004-09-02 | 2012-10-09 | Vertex Pharmaceuticals Incorporated | Quinazolines useful as modulators of ion channels |
| ATE549314T1 (de) * | 2004-12-17 | 2012-03-15 | Vertex Pharma | Verfahren zur herstellung von 4-aminochinazolinen |
| ES2377988T3 (es) * | 2005-11-14 | 2012-04-03 | Vertex Pharmaceuticals, Inc. | Quinazolinas útiles como moduladores de canales iónicos controlados por voltaje |
| KR20130095772A (ko) | 2010-10-05 | 2013-08-28 | 퍼듀 퍼머 엘피 | 나트륨 채널 차단제로서 퀴나졸린 화합물 |
| KR101657616B1 (ko) * | 2013-05-24 | 2016-09-19 | 주식회사유한양행 | 피리미딘 고리를 포함하는 바이사이클릭 유도체 및 그의 제조방법 |
| WO2019089693A1 (en) * | 2017-10-31 | 2019-05-09 | Southern Research Institute | Substituted quinazoline sulfonamides as thioredoxin interacting protein (txnip) inhibitors |
| MX2021015605A (es) * | 2019-06-27 | 2022-02-16 | Glaxosmithkline Ip Dev Ltd | Compuestos 2,3-dihidroquinazolin como inhibidores nav1.8. |
| TWI813493B (zh) * | 2021-07-20 | 2023-08-21 | 友達光電股份有限公司 | 顯示裝置 |
| JP2025516005A (ja) * | 2022-04-25 | 2025-05-23 | サイトワン セラピューティクス インコーポレイテッド | 疼痛の処置のためのｎａｖ１．８の二環式複素環アミド阻害剤 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI20021314A0 (fi) * | 2002-07-03 | 2002-07-03 | Nokia Corp | Tiedonsiirtomenetelmä ja järjestely |
| CL2004000409A1 (es) * | 2003-03-03 | 2005-01-07 | Vertex Pharma | Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu |
| US7713983B2 (en) * | 2003-03-03 | 2010-05-11 | Vertex Pharmaceuticals Incorporated | Quinazolines useful as modulators of ion channels |
| KR20070057914A (ko) * | 2004-09-02 | 2007-06-07 | 버텍스 파마슈티칼스 인코포레이티드 | 이온 채널 조절인자로서 유용한 퀴나졸린 |
| US7718658B2 (en) * | 2004-09-02 | 2010-05-18 | Vertex Pharmaceuticals Incorporated | Quinazolines useful as modulators of ion channels |
| US7928107B2 (en) * | 2004-09-02 | 2011-04-19 | Vertex Pharmaceuticals Incorporated | Quinazolines useful as modulators of ion channels |
| US8283354B2 (en) * | 2004-09-02 | 2012-10-09 | Vertex Pharmaceuticals Incorporated | Quinazolines useful as modulators of ion channels |
| ATE549314T1 (de) * | 2004-12-17 | 2012-03-15 | Vertex Pharma | Verfahren zur herstellung von 4-aminochinazolinen |
| ES2377988T3 (es) * | 2005-11-14 | 2012-04-03 | Vertex Pharmaceuticals, Inc. | Quinazolinas útiles como moduladores de canales iónicos controlados por voltaje |
-
2006
- 2006-11-13 ES ES06837387T patent/ES2377988T3/es active Active
- 2006-11-13 AU AU2006315675A patent/AU2006315675B2/en not_active Ceased
- 2006-11-13 EP EP06837387A patent/EP1957482B1/en not_active Not-in-force
- 2006-11-13 US US11/598,576 patent/US8158637B2/en not_active Expired - Fee Related
- 2006-11-13 CN CNA2006800507452A patent/CN101356168A/zh active Pending
- 2006-11-13 CA CA002628650A patent/CA2628650A1/en not_active Abandoned
- 2006-11-13 AT AT06837387T patent/ATE540033T1/de active
- 2006-11-13 WO PCT/US2006/043895 patent/WO2007058989A2/en not_active Ceased
- 2006-11-13 JP JP2008540234A patent/JP2009515892A/ja active Pending
- 2006-11-13 RU RU2008123811/04A patent/RU2008123811A/ru not_active Application Discontinuation
- 2006-11-13 ZA ZA200804043A patent/ZA200804043B/xx unknown
- 2006-11-13 MX MX2008006303A patent/MX2008006303A/es not_active Application Discontinuation
- 2006-11-13 KR KR1020087014446A patent/KR20080073749A/ko not_active Withdrawn
- 2006-11-13 NZ NZ568393A patent/NZ568393A/en not_active IP Right Cessation
- 2006-11-14 TW TW095142123A patent/TW200804348A/zh unknown
- 2006-11-14 AR ARP060104980A patent/AR057576A1/es unknown
-
2008
- 2008-03-18 US US12/050,289 patent/US8809353B2/en active Active
- 2008-06-13 NO NO20082746A patent/NO20082746L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NZ568393A (en) | 2011-08-26 |
| EP1957482B1 (en) | 2012-01-04 |
| CA2628650A1 (en) | 2007-05-24 |
| AU2006315675A1 (en) | 2007-05-24 |
| EP1957482A2 (en) | 2008-08-20 |
| JP2009515892A (ja) | 2009-04-16 |
| ZA200804043B (en) | 2010-01-27 |
| US8158637B2 (en) | 2012-04-17 |
| ES2377988T3 (es) | 2012-04-03 |
| ATE540033T1 (de) | 2012-01-15 |
| NO20082746L (no) | 2008-08-08 |
| WO2007058989A2 (en) | 2007-05-24 |
| AU2006315675B2 (en) | 2012-06-07 |
| MX2008006303A (es) | 2009-02-26 |
| US20080221137A1 (en) | 2008-09-11 |
| KR20080073749A (ko) | 2008-08-11 |
| WO2007058989A3 (en) | 2007-09-07 |
| CN101356168A (zh) | 2009-01-28 |
| US8809353B2 (en) | 2014-08-19 |
| TW200804348A (en) | 2008-01-16 |
| RU2008123811A (ru) | 2009-12-27 |
| US20080167305A1 (en) | 2008-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY39032A (es) | Compuestos heterocíclicos como agentes antivirales | |
| AR057576A1 (es) | Derivados sustituidos de pirrolidin-quinazolinas inhibidores de canales de sodio dependientes de voltaje, composiciones farmaceuticas que los contienen y usos, entre otros, en el tratamiento de una variedad de condiciones de dolor | |
| AR034555A1 (es) | Compuestos de 1,4-dihidropiridina como antagonistas de bradicinina; composicion farmaceutica, compuesto intermediario, procedimiento para preparar dichos compuestos | |
| NO20073357L (no) | 5-karboksamid substituerte tiazol derivater som reagerer med ionekanaler, i saerdeleshet med ionekanaler fra Kv familien | |
| AR041566A1 (es) | Derivados de indol utiles para el tratamiento de enfermedades | |
| AR003453A1 (es) | Inhibidores de agregado de plaquetas, su uso en la fabricacion de medicamentos, composicion farmaceutica que los contiene y procedimiento para la preparacion de dichos inhibidores | |
| NO20076197L (no) | Nye 2-azetidinonderivater anvendbare i behandling av hyperlipidemiske tilstander | |
| AR052887A1 (es) | Derivados de tiazol, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para tratar enfermedades mediadas por la inhibicion de la protein quinasa | |
| UY38614A (es) | Derivados de benzodiazepinas como inhibidores del rsv | |
| AR024060A1 (es) | Nuevos compuestos farmaceuticamente activos | |
| BRPI0114704B8 (pt) | composto de imidazol fundido a arila ou heteroarila, suas composições farmacêuticas, bem como seu uso | |
| BR0108893B1 (pt) | composiÇço farmacÊutica contendo derivados de azetidina, composto derivado de azetidina, e, processo para a preparaÇço de compostos. | |
| CY1109457T1 (el) | Παραγωγο aminoαλκοολης ή παραγωγο φωσφονικου οξεος και φαρμακευτικη συνθεση που τα περιεχει | |
| BRPI0413876A (pt) | tienopiridin-fenilacetamidas e seus derivados úteis como agentes antiangiogênicos | |
| BR0213522B1 (pt) | compostos derivados de hidroxipirimidinona, composição farmacêutica, e, uso de um composto | |
| UY28578A1 (es) | Derivados de amida | |
| TN2010000026A1 (fr) | Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met | |
| AR058287A1 (es) | Derivados de isoquinolina y composicion farmaceutica | |
| UY39642A (es) | Compuestos heterocíclicos antivirales | |
| MX2022015886A (es) | Derivados de amidopirimidona. | |
| AR129003A1 (es) | Compuestos heterocíclicos antivirales | |
| AR044200A1 (es) | Composicion de fondaparinux sodico de alta pureza ,un procedimiento de preparacion de esta composicion y composiciones farmaceuticas que la contienen como principio activo | |
| GEAP202516786A (en) | 2-amino-n-(4-amino-3,4-dioxo-1-(2-oxopyrrolidin-3-yl)butan-2-yl)benzamide derivatives as protease inhibitors for treating or preventing coronavirus infection | |
| AR042480A1 (es) | Derivados de la quinazolina para el trtamiento del crecimiento celular anormal | |
| EE9800233A (et) | Benso[c]kinolisiini derivaadid, nende valmistamine ja kasutamine 5a-reduktaasi inhibiitoritena |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |